FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to benzamide compounds of formula (IA) where R2, R3 and R5 each is independently selected from hydrogen or metal or their pharmaceutically acceptable salts. Compounds of formula (IA) are inhibitors of histone deacetilase.
EFFECT: elaboration of method of obtaining formula (IA) compounds, pharmaceutical composition, which contains them, and their application for preparation of medication for application as anti-proliferative means for prevention or treatment of tumours or other proliferative conditions, which are sensitive to inhibition of histone deacetilase.
17 cl, 2 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
HISTONE DEACETYLASE INHIBITORS | 2014 |
|
RU2673819C2 |
TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | 2009 |
|
RU2561104C2 |
BENZOYLAMINOHETEROCYCLYL COUMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | 2007 |
|
RU2440992C2 |
HISTONE DEACETYLASE INHIBITORS | 2016 |
|
RU2720678C2 |
HISTONE DEACETYLASE INHIBITORS | 2008 |
|
RU2453536C2 |
AMINOPYRIMIDINES AS KINASE INHIBITORS | 2006 |
|
RU2427578C2 |
PRIMARY CARBOXAMIDES AS BTK INHIBITORS | 2014 |
|
RU2708395C2 |
JAK-INHIBITING TRIAZOLOPYRIDINE COMPOUNDS AND METHODS | 2009 |
|
RU2560153C2 |
PYRIDYL-PIPERIDINE ANTAGONISTS OF OREXIN RECEPTORS | 2008 |
|
RU2470021C2 |
DERIVATIVES OF 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE EFFECTIVE AS CB1 MODULATORS | 2005 |
|
RU2375349C2 |
Authors
Dates
2012-04-27—Published
2006-10-17—Filed